Sep 09, 2019 / 05:05PM GMT
David Ryan Lewis - Morgan Stanley, Research Division - MD
All right. Let's go ahead and get started here, a big room. My name is David Lewis, medical device analyst here at Morgan Stanley. It's my pleasure to have with us here members of management from Baxter as we kind of progress through the afternoon session here post-lunch. I donât see any food comas out there just yet. Well, it's my pleasure to have with us Joe Almeida, the CEO; and Clare Trachtman, VP, Investor Relations. And we're going to jump right into Q&A.
Questions and Answers:
David Ryan Lewis - Morgan Stanley, Research Division - MDAnd Joe, not to kind of engage in self-promotion of our rating to begin the year, but we talked about a couple of things as it relates to our upgrade of Baxter earlier this year. One was sort of stabilizing the core IV solutions business, the pathway to 2020 acceleration and sort of deploy the balance sheet. Could you just share with us where you think you are kind of across those 3 components here, 9 months through the year?
José
Trustpilot
